Lonza announced on 16 November 2021 that it has invested in additional microbial development capabilities at its Visp, Switzerland, site and will increase the capacity of its development services targeting microbial-derived proteins by expanding laboratory space and equipment, which will be ready to use by the end of 2021. Under the expansion, a dedicated pilot suite will be installed, housing a 50-L fermenter and corresponding downstream equipment. Source: Biopharm International 18/11/2021